TheEdgeResearch
Home / Stocks / FBRX

Forte Biosciences, Inc. (FBRX)

NASDAQ Healthcare Biotechnology
$76.99 ▲ +0.00%
Market Cap
$1.63B
Sector
Healthcare
Industry
Biotechnology
Beta
2.65
52-Wk Range
—
CEO
Paul A. Wagner
Country
US
Currency
USD

Forte Biosciences, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Dallas, TX, US. The stock last traded at $76.99, up 0.00% on the session, giving a market capitalisation of $1.63B. On trailing twelve-month figures it carries a trailing P/E of -16.77, a net margin of 0.0%. Its beta of 2.65 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-16.77
Price / Sales
0.00
Price / Book
9.96
EV / EBITDA
-18.37
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
—
Debt / equity
0.00
Current ratio
10.01
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Capital Market
Employees
23
IPO date
2017-04-13
Headquarters
Dallas, TX, US
About Forte Biosciences, Inc.

Forte Biosciences, Inc. is a U.S.-based biopharmaceutical company currently in its clinical development phase. The firm's key initiative involves advancing the FB-102 program, which is designed to tackle a variety of autoimmune conditions, notably vitiligo and alopecia areata. Their main offices are situated in Dallas, Texas.

Comparable companies

Forte Biosciences, Inc. is most often compared with the following Healthcare names:

ACTUALECAPLTCRBPCRDFELTXFATEMOLNNKTXPEPG
More research on FBRX
FBRX technical analysis FBRX TheEdge Score Compare against peers
Open full interactive analysis & DCF →